Viragen shares surge on avian flu results for Multiferon

Viragen of Plantation, FL, announced that an in-vitro study of its drug Multiferon shows that it may work against the avian flu virus H5N1. The Southern Research Institute conducted the early-stage study, concluding that it appeared more active than other products that are being used to combat the virus. Viragen said the results make Multiferon a prime candidate for further study. "Multiferon may represent a different approach to treatment in that it has been shown to exhibit rather broad anti-viral activity," says Viragen CEO Charles A. Rice. "I can also confirm that separate studies are ongoing in a variety of other emerging viral threats in cooperation with a number of independent investigators."

- read this press release for more

ALSO: The news left investors scrambling to buy Viragen stock, sending shares up more than 20 percent late Friday after the company announced the results. Report

PLUS: The US is unprepared for an avian flu pandemic and won't be able to produce sufficient quantities of a vaccine for three to five years, according to the blunt assessment of HHS Secretary Mike Leavitt. Report

FINALLY: Veterinarians warn that Chinese vaccination teams sent to eradicate the avian flu virus may well end up spreading the disease if they aren't extremely careful. Article

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.